Tags

Type your tag names separated by a space and hit enter

A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
J Clin Gastroenterol. 2011 Sep; 45(8):679-83.JC

Abstract

BACKGROUND

Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial.

AIMS

This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.

METHODS

Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week.

RESULTS

The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group.

CONCLUSIONS

S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.

Authors+Show Affiliations

Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21301358

Citation

Choi, Chang Hwan, et al. "A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces Boulardii in Irritable Bowel Syndrome: Effect On Quality of Life." Journal of Clinical Gastroenterology, vol. 45, no. 8, 2011, pp. 679-83.
Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679-83.
Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J. S., & Myung, S. J. (2011). A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. Journal of Clinical Gastroenterology, 45(8), 679-83. https://doi.org/10.1097/MCG.0b013e318204593e
Choi CH, et al. A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces Boulardii in Irritable Bowel Syndrome: Effect On Quality of Life. J Clin Gastroenterol. 2011;45(8):679-83. PubMed PMID: 21301358.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. AU - Choi,Chang Hwan, AU - Jo,Sun Young, AU - Park,Hyo Jin, AU - Chang,Sae Kyung, AU - Byeon,Jeong-Sik, AU - Myung,Seung-Jae, PY - 2011/2/9/entrez PY - 2011/2/9/pubmed PY - 2011/12/15/medline SP - 679 EP - 83 JF - Journal of clinical gastroenterology JO - J Clin Gastroenterol VL - 45 IS - 8 N2 - BACKGROUND: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. METHODS: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. RESULTS: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. CONCLUSIONS: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. SN - 1539-2031 UR - https://www.unboundmedicine.com/medline/citation/21301358/A_randomized_double_blind_placebo_controlled_multicenter_trial_of_saccharomyces_boulardii_in_irritable_bowel_syndrome:_effect_on_quality_of_life_ L2 - https://doi.org/10.1097/MCG.0b013e318204593e DB - PRIME DP - Unbound Medicine ER -